First Opinion By Natalie Ma My company is developing new antibiotics. My resistant infection showed me we need them now
Pharmalot By Ed Silverman Older Americans bore the brunt of antibiotic-resistant infections, study finds
First Opinion By Sevahn Vorperian and Stephen Quake The PASTEUR Act can help win the war against superbugs
First Opinion Podcast By Patrick Skerrett Listen: Antibiotic experts on the threat of antimicrobial resistant superbugs
First Opinion By David Hyun and Rachel Zetts Many hospitalized Covid-19 patients are given antibiotics. That’s a problem
First Opinion By Julie L. Gerberding Antibiotic resistance: the hidden threat lurking behind Covid-19
First Opinion By Janet Midega New global data showing 1.27 million deaths a year reveal the urgent need to address antimicrobial resistance
Pharmalot By Ed Silverman McDonald’s accused of dragging its feet on goal of reducing antibiotic use in beef supplies
Pharmalot By Ed Silverman A lack of access: Pharma is failing to ensure new antibiotics will be available to poor countries, analysis finds
First Opinion Podcast By Patrick Skerrett Listen: An antibiotic expert on her body’s stinging betrayal by these drugs
In the Lab By Peter Andrey Smith In the hunt for novel antibiotics, will new technology overtake underwater exploration?
Pharma By Ed Silverman Drug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them?
Pharmalot By Ed Silverman Lawmakers revive legislation to accelerate the development of new antibiotics
Pharmalot By Ed Silverman WHO warns the world is still failing to develop desperately needed antibiotics
Pharmalot By Ed Silverman EPA rule that could help citrus growers is challenged over concerns about antibiotic resistance
Pharmalot By Ed Silverman Antibiotic stewardship may be improving at U.S. hospitals, but new targets are still needed
Pharmalot By Ed Silverman Antibiotic prescribing during the pandemic raises concern about drug resistance
First Opinion By Michelle McMurry-Heath The Biden administration’s pandemic agenda must not ignore superbugs
Politics By Matthew Herper Sen. Cassidy explains why he’s backing a bill aimed at drug-resistant bacteria
Pharmalot By Ed Silverman Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline
First Opinion By Jowa (Zhuo) Shi and Ateev Mehrotra Inappropriately prescribed antibiotics will likely accompany the winter surge of Covid-19
Pharmalot By Ed Silverman New bill would create a subscription payment model to jumpstart antibiotic development
Pharmalot By Ed Silverman Doctors say antibiotic resistance is an issue — but most say they’re not part of the problem
First Opinion By Kevin Outterson and John Rex We need new antimicrobials to prevent the next infectious disease crisis
Special Report By Gardiner Harris and Alex W. Palmer — The Wire China has near-total control of the world’s antibiotic supply. Is America at risk as a result?
First Opinion By Isaac Stoner Saving lives should be good business. Why doesn’t that apply to finding new antibiotics?
Pharmalot By Ed Silverman WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’
Pharmalot By Ed Silverman Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire